Kiniksa Pharmaceuticals Ltd (KNSA) — Cash Flow-to-Debt Ratio
Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow-to-Debt Ratio of 0.20x as of June 2026, meaning its operating cash flow of $47.46 Million could theoretically repay 0% of its total liabilities ($241.96 Million) in one year. See Kiniksa Pharmaceuticals Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kiniksa Pharmaceuticals Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Kiniksa Pharmaceuticals Ltd across 10 annual periods. For the full cash flow conversion analysis, see how efficiently does Kiniksa Pharmaceuticals Ltd generate cash.
Annual Cash Flow-to-Debt Ratio for Kiniksa Pharmaceuticals Ltd (2016–2025)
Year-by-year debt coverage analysis for Kiniksa Pharmaceuticals Ltd. Check cash flow quality index of Kiniksa Pharmaceuticals Ltd to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | $25.69 Million | $196.03 Million | ▼ -27.5% |
| 2024 | 0.18x | $25.69 Million | $142.12 Million | ▲ +18.9% |
| 2023 | 0.15x | $13.30 Million | $87.48 Million | ▲ +66.3% |
| 2022 | 0.09x | $5.81 Million | $63.52 Million | ▲ +103.5% |
| 2021 | -2.64x | $-126.30 Million | $47.76 Million | ▲ +27.3% |
| 2020 | -3.64x | $-136.53 Million | $37.53 Million | ▲ +33.1% |
| 2019 | -5.44x | $-158.37 Million | $29.11 Million | ▼ -186.7% |
| 2018 | -1.90x | $-81.01 Million | $42.70 Million | ▼ -418.4% |
| 2017 | -0.37x | $-50.22 Million | $137.20 Million | ▼ -37.6% |
| 2016 | -0.27x | $-21.87 Million | $82.20 Million | — |